TRIAMCINOLONE ACETONIDE ointment

Land: Bandaríkin

Tungumál: enska

Heimild: NLM (National Library of Medicine)

Virkt innihaldsefni:

Triamcinolone Acetonide (UNII: F446C597KA) (Triamcinolone Acetonide - UNII:F446C597KA)

Fáanlegur frá:

Taro Pharmaceuticals U.S.A., Inc.

INN (Alþjóðlegt nafn):

Triamcinolone Acetonide

Samsetning:

Triamcinolone Acetonide 1 mg in 1 g

Stjórnsýsluleið:

TOPICAL

Gerð lyfseðils:

PRESCRIPTION DRUG

Ábendingar:

Triamcinolone Acetonide Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Vörulýsing:

Triamcinolone Acetonide Ointment USP, 0.1% is supplied in 15 g (NDC 51672-1284-1), 30 g (NDC 51672-1284-2), and 80 g (NDC 51672-1284-8) tubes. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Leyfisstaða:

Abbreviated New Drug Application

Vara einkenni

TRIAMCINOLONE ACETONIDE- TRIAMCINOLONE ACETONIDE OINTMENT
TARO PHARMACEUTICALS U.S.A., INC.
----------
TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.1%
FOR DERMATOLOGIC USE ONLY
NOT FOR OPHTHALMIC USE
RX ONLY
DESCRIPTION
The topical corticosteroids constitute a class of primarily synthetic
steroids used as anti-inflammatory
and anti-pruritic agents. The steroids in this class include
triamcinolone acetonide. Triamcinolone
acetonide is designated chemically as pregna-1,4-diene-3,20-dione,
9-fluoro-11,21-dihydroxy-16,17-
[(1-methylethylidene)bis(oxy)]-, (11β,16α)-. The structural formula
is:
Molecular Weight: 434.51
Molecular Formula: C
H FO
Each gram of Triamcinolone Acetonide Ointment USP, 0.1% contains 1 mg
triamcinolone acetonide, in
an ointment base of fractionated coconut oil and white petrolatum,
with methylparaben and propylparaben
as preservatives.
CLINICAL PHARMACOLOGY
Topical corticosteroids share anti-inflammatory, anti-pruritic and
vasoconstrictive actions. The
mechanism of anti-inflammatory activity of the topical corticosteroids
is unclear. Various laboratory
methods, including vasoconstrictor assays, are used to compare and
predict potencies and/or clinical
efficacies of the topical corticosteroids. There is some evidence to
suggest that a recognizable
correlation exists between vasoconstrictor potency and therapeutic
efficacy in man.
PHARMACOKINETICS
The extent of percutaneous absorption of topical corticosteroids is
determined by many factors
including the vehicle, the integrity of the epidermal barrier, and the
use of occlusive dressings. Topical
corticosteroids can be absorbed from normal intact skin. Inflammation
and/or other disease processes in
the skin increase percutaneous absorption. Occlusive dressings
substantially increase the percutaneous
absorption of topical corticosteroids. Thus, occlusive dressings may
be a valuable therapeutic adjunct
for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION).
Once absorbed
24
31
6
through the skin, topical corticosteroids are handled throu